Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 816,000 Ordinary Shares on June 5, 2014.
- Price Range: Highest price paid was 1,588.50 pence; lowest price paid was 1,573.50 pence.
- Treasury Holdings (Settled): 496,520,414 shares (9.28% of total issued share capital).
- Treasury Holdings (Including Unsettled): 498,789,914 shares (10.28% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,854,192,248 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 816,000 shares for treasury. This action increased the percentage of total voting rights held in treasury from the prior settled position to 10.28% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in treasury (496,520,414 settled) against the company's latest 20-F annual report.
- Confirm the calculation of total voting rights (4,854,192,248) for disclosure threshold assessments.
- Note that the 10.28% treasury holding figure includes shares purchased but not yet settled.